Organovo Holdings, Inc. (ONVO) Stock Analysis & Investment Frameworks
Organovo Holdings, Inc. (ONVO) stock analysis on Invetso. Review Organovo Holdings, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Organovo Holdings, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Organovo Holdings, Inc. Key Financial Metrics
- Market Cap: $3.67M
- Revenue: $131000.00
- ROE: -612.23%
- ROIC: -498.96%
- Dividend Yield: N/A
About Organovo Holdings, Inc.
Organovo Holdings, Inc. is a biotechnology firm that specializes in engineering sophisticated 3D tissues designed to accurately mimic critical facets of human diseases. Central to its operations is a comprehensive 3D human tissue platform, which features the company's proprietary NovoGen Bioprinters. These automated devices are crucial for fabricating complex, living 3D tissues from mammalian cells. The platform also includes supporting technologies necessary for creating specialized "bio-inks" and for the bioprinting of multi-cellular tissues with intricate structures. Organovo supplies specific products, such as ExVive human liver tissue and ExVive human kidney tissue, which are employed for predictive preclinical evaluation of investigational drug compounds. The company was founded in 2007 and maintains its corporate headquarters in Solana Beach, California.